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 5 
Summary box 6 
What is the key question? 7 
What are the characteristics of the UK’s general asthma population, including all phenotypes and 8 
ages, and how are these associated with the risk of an exacerbation? 9 
What is the bottom line? 10 
Many differences in demographics, clinical characteristics, and exacerbation rates, were found 11 
between the four generations of asthma patients; the oldest (≥55 years) cohort, followed by the 12 
youngest (<5 years) cohort, had the most severe asthma with the highest exacerbation rates. 13 
Why read on? 14 
This is the first description of the UK’s general asthma population and includes all those with current 15 
asthma, from infants to old age.  16 
 17 
Abstract 18 
BACKGROUND: 19 
Few studies have examined the characteristics of a general asthma population; most have focussed 20 
on more severe patients or severe exacerbations. 21 
METHODS: 22 
This population-based cohort study, April 2007 to September 2015, used linked primary and secondary 23 
care electronic healthcare records (Clinical Practice Research Datalink, Hospital Episode Statistics). 24 
Characteristics of four age cohorts: ‘Under 5s’, ‘5 to 17s’, ‘18 to 54s’, ‘55+’, were described. 25 
Exacerbation risk factors, including asthma severity (measured by the British Thoracic Society stepwise 26 
approach), were assessed using Poisson regression. 27 
RESULTS: 28 
424,326 patients with current asthma were eligible (N, median follow-up: ‘Under 5s’=17,320, 1 year; 29 
‘5 to 17s’=82,707, 3.3 years; ’18 to 54s’=210,724, 4 years; ‘55+’=113,575, 5.1 years). Over 60% of the 30 
total study population had mild asthma (BTS steps 1/2). There were differences between the cohort’s 31 
characteristics, including by gender, disease severity and exacerbation pattern. The rate of 32 
exacerbations was highest in the oldest cohort and lowest in the ‘5 to 17s’ cohort (rate per 10 person-33 
years, (95% CI), ‘Under 5s’=4.27 (4.18-4.38), ‘5 to 17s’=1.48 (1.47-1.50), ’18 to 54s’=3.22 (3.21-3.24), 34 
‘55+’=9.40 (9.37-9.42)).  In all cohorts, exacerbation rates increased with increasing asthma severity, 35 
after adjusting for confounders including gender, socioeconomic status, smoking, BMI, atopy, rhinitis, 36 
gastroesophageal reflux, anxiety, depression and COPD. 37 
CONCLUSION: 38 
The majority of UK asthma patients had mild asthma and did not experience an exacerbation during 39 
follow-up. Patients aged >55 years had the lowest proportion with mild asthma and highest rate of 40 
exacerbations; the opposite was found in patients aged between 5 to 18 years. 41 
 42 
Introduction 43 
Asthma is a common disease and its lifetime prevalence in the UK continues to rise1. Internationally, 44 
the UK ranks as having one of the highest prevalence and mortality rates in Europe2,3. Asthma causes 45 
a significant burden to the NHS across the spectrum of ages, with 5.4 million people receiving 46 
treatment and approximately 65,000 hospital admissions yearly4. In addition it leads to a significant 47 
societal burden including absence from work and school.  48 
Most asthma patients do not require secondary care intervention yet there is limited knowledge on 49 
the characterisation of national asthma populations. To date, epidemiological studies have focussed 50 
on patients with more severe disease, distinct phenotypes, or have separated those with childhood-51 
onset from adult-onset asthma. In addition, most published reports on exacerbations have analysed 52 
only hospital admissions or Accident & Emergency (A&E) visits. Currently, we do not have 53 
comprehensive knowledge on the UK’s general asthma population; this is needed to help us 54 
understand the natural history of asthma and guide population-level public health measures.  55 
Over 98% of the UK population is registered with a general practitioner (GP)5. Most asthma patients 56 
first present to their GP who makes the diagnosis based on their respiratory symptoms, signs and test 57 
results; in patients with insufficient evidence, such as children under 5 years who cannot perform 58 
spirometry, a period of watchful waiting or monitored treatment may be advocated. Primary care 59 
electronic healthcare records, originating from routine clinical practice, capture this and a huge 60 
amount of other clinical and demographic information in a longitudinal record.  61 
We have used national electronic healthcare records to describe, for the first time, the UK's asthma 62 
population, laying out the differences and similarities that exist between the generations using four 63 
consecutive age cohorts between infancy and old age. We have assessed several factors that may be 64 
associated with an increased risk of an exacerbation. 65 
 66 
Methods 67 
Data sources 68 
Clinical Practice Research Datalink (CPRD) included 674 GP practices and current coverage of over 11.3 69 
million patients who represent the UK’s population with respect of age, gender, BMI and ethnicity6. 70 
Approximately 60% of CPRD practices have patient-level linkage to Hospital Episode Statistics (HES) 71 
data (collected during a patient’s visit to an NHS hospital), Index of Multiple Deprivation (IMD) and 72 
Office of National Statistics mortality data.  73 
Study design and population 74 
We conducted a population-wide open cohort study. The study population consisted of patients in 75 
CPRD linked practices with validated Read codes (a clinical terminology system) indicating prevalent 76 
or incident asthma7. Patients were eligible if a code for asthma had been recorded at ≤2 years prior to 77 
study entry if aged <18 years, or ≤3 years if aged ≥18 years (Figure 1). Patients entered the study at 78 
the latest of their asthma diagnosis date, the date the practice began recording research quality data, 79 
or 1st April 2007. Patient follow-up was censored at the earliest of 30th September 2015, death, 80 
transfer out of CPRD practice, linkage end date or practice last collection date. The patient’s age at 81 
study entry dictated which cohort they entered. Age categories were based on the age distinctions 82 
used in the BTS asthma guidance8: under 5 years old, 5-12 years old and adolescents were combined 83 
in the 5-17s year cohort, and the adult cohort was split into two cohorts due to the possible 84 
confounding from COPD after 55 years old. 85 
Outcome and variables 86 
The main outcome was asthma exacerbations. An exacerbation was defined as ≤300mg oral 87 
corticosteroids (OCS) (not prescribed during an annual asthma review), or an A&E visit, or hospital 88 
admission. A cut-off of ≤150mg OCS was used for children <5 years old. Exacerbations recorded within 89 
14 days after the index one were considered part of the same exacerbation. Level of care of each 90 
exacerbation was documented as the highest level per episode. Incident lower respiratory tract 91 
infections treated with antibiotics (Ax-LRTIs) were also measured, by identifying specific Read codes 92 
(available upon request) with same day prescription of appropriate antibiotics. 93 
Body mass index (BMI) was measured using kg/m2 (z-scores were used if <5 years old). A history of 94 
atopy, rhinitis, gastroesophageal reflux (reflux), anxiety and depression were recorded using 95 
appropriate Read codes (available upon request). COPD was classified by Read codes, a smoking 96 
history, and age >35 years9. The British Thoracic Society (BTS) stepwise approach (incorporating 97 
inhaler class and dose) is a recommended evidence-based method of measuring asthma severity8. 98 
Using the 2016 guidelines, patients were classified by their highest BTS step (most severe asthma) 99 
using all medications prescribed during the year before their study start date. Step 6 is ‘continuous or 100 
frequent’ OCS use; we defined this as ≥6 annual OCS prescriptions that must have occurred in ≥2 101 
yearly-quarters (a yearly-quarter was 3 consecutive months). Approximately 20% of inhaled 102 
corticosteroid (ICS) prescriptions did not have a precise dose recorded; using the BTS guidelines and 103 
the type of ICS device and dosage prescribed the ICS dose levels were imputed with good accuracy. 104 
Statistical analysis 105 
Baseline characteristics were tabulated for each cohort. To take into account multiple exacerbations, 106 
a repeated measures Poisson regression model was used to calculate crude rate ratios of 107 
exacerbations. This model was also used to determine the relative rates of exacerbations by BTS step, 108 
adjusting for: gender, age, IMD (socioeconomic index, 1 is least deprived), BMI, smoking status, atopy, 109 
rhinitis, reflux, anxiety, depression and COPD status. Where >20% of the data were missing the 110 
variable was excluded from the regression model. The data were also modelled using Poisson 111 
regression and time to first exacerbation during study follow-up; results were displayed by Kaplan-112 
Meier graphs. 113 
Ethics  114 
The protocol for this research was approved by the Independent Scientific Advisory Committee (ISAC) 115 
for MHRA Database Research (protocol 16_067), the approved protocol was made available during 116 
peer review.  Generic ethical approval for observational research using the CPRD with approval from 117 
ISAC has been granted by a Health Research Authority Research Ethics Committee (East Midlands – 118 
Derby, REC reference number 05/MRE04/87).  119 
 120 
Results 121 
Patient characteristics  122 
In the total study population there were 424,326 patients with current asthma. The number of 123 
patients and follow-up varied between cohorts, the smallest and shortest follow-up was in the ‘Under 124 
5s’ and the largest, with a longer follow-up, was the ’18 to 54s’ cohort (‘Under 5s’ N=17,320, IQR 0.5-125 
1.8 years; ‘5 to 17s’ N=82,707, IQR 1.4-5.8; ’18 to 54s’ N=210,724, IQR 1.7-6.9 years; ‘55+’ N=113,575, 126 
IQR 2.4-7.6) (Table 1). Female prevalence increased with increasing cohort age and became the 127 
dominant gender from 18 years onwards (Table 1). Over 70% in the ‘Under 5s’ cohort were aged 128 
between 3 and 5 years old (Table 1). In the ‘55+’ cohort the numbers of patients were inversely 129 
proportional to the age group. The highest percentage of smokers were in the ’18 to 54s’ cohort 130 
(current 25.9%) and ex-smokers in the ‘55+’ cohorts (ex-smoker 49.2%) (Table 1). Recorded BMI was 131 
predominantly either normal or underweight if cohort age was <18 years, but normal or above if 132 
cohort age was ≥ 18 years (Table 1).  133 
Taking the total cohort as a whole (all ages), 35% (149,338) of patients were not taking regular asthma 134 
medication and 27% (112,937) were taking an ICS at the lowest dose appropriate for their age. The 135 
proportion in each BTS step varied with each cohort (Table 1 & Figure 2). Around 70% of patients <55 136 
years old were in BTS step 1 or 2, only in the ‘Under 5s’ cohort were there more in BTS step 2 than 1 137 
(Table 1). The ‘55+’ cohort had the smallest proportion with patients on BTS steps 1 or 2 (44%). All the 138 
cohorts had a very low proportion in BTS step 6 (< 2%).  139 
The proportion of patients with atopy was highest in the two youngest cohorts (<18 years) (Table 1). 140 
The proportion of patients with rhinitis, reflux, anxiety or depression was highest in the two oldest 141 
cohorts (≥18 years) (Table 2). Just under one quarter aged ≥ 55 years had a co-existent diagnosis of 142 
COPD (Table 1), of these 66% had a COPD diagnosis after their asthma diagnosis. 143 
Exacerbation characteristics  144 
The rate of exacerbations was highest in the oldest age group, followed by the youngest age group, 145 
and lowest in the ‘5 to 17s’ cohort (exacerbations per 10 person years: ‘55+’=9.4 (95%CI 9.37-9.42), 146 
‘Under 5s’=4.27 (95%CI 4.18-4.38), ’18 to 54s’=3.22 (95% CI 3.21-3.24), ‘5 to 17s’= 1.48 (95% CI 1.47-147 
1.5)) (Table 2). Of those who did exacerbate, the majority had ≤1 exacerbation per year, in cohorts 148 
aged ≥5 years (Ann. Freq. ≤1/year: ‘5 to 17s’=86.9%; ’18 to 54s’=81.3%; ‘55+’=65%); the opposite was 149 
found in the ‘Under 5s’ cohort, in whom just over half experienced >1 exacerbation per year (54.7%) 150 
(Table 2 & Figure 3). Around 85% of exacerbations in each cohort did not require over-night 151 
hospitalisation (‘Under 5s’= 85.6%, ‘5 to 17s’= 85.2%, ‘18 to 54s’= 83.1%, ‘55+’= 88.7%). All patients 152 
were most likely to see their GP as their maximum level of care; the oldest age cohort had a lower 153 
proportion of hospitalised exacerbations, but highest proportion of asthma deaths (Table 2). 154 
The rate of Ax-LRTIs was much lower than the rate of exacerbations; the rate was highest in the ‘55+’ 155 
cohort and lowest in the ‘5 to 17s’ cohort (‘55+’=1.93 (95% CI 1.92-1.94) exacerbations per 10 person-156 
years, ‘5 to 17s’=0.22 (95% CI 0.21-0.22) exacerbations per 10 person-years). Of those with an Ax-LRTI, 157 
<10% occurred at the time of, or 14 days after an exacerbation (‘Under 5s’= 5%, ‘5 to 17s’= 4.9%, ‘18 158 
to 54s’= 8.3%, ‘55+’= 7.3%) and ≤1% of Ax-LRTIs preceded an exacerbation within 14 days (‘Under 5s’= 159 
0.6%, ‘5 to 17s’= 0.4%, ‘18 to 54s’= 0.9%, ‘55+’= 1%). 160 
The rate of exacerbations increased with increasing asthma severity (BTS step) in every cohort, with 161 
the lowest rate, 0.73 (95% CI 0.7-0.77) exacerbations per 10 person-years, in BTS step 1 in ‘5 to 17s’ 162 
cohort and the highest rate, 60.2 (95% CI 57.97-62.52) exacerbations per 10 person-years, in BTS step 163 
6 in the ‘55+’ cohort (Table 3). 164 
Effect of demographic and clinical characteristics on exacerbation rates (univariable analysis) 165 
Female gender was significantly associated with exacerbation risk in all cohorts except for the ‘5 to 166 
17s’ cohort; the relative rate decreased in the ‘Under 5s’ but increased in the oldest two cohorts 167 
(Female: ‘Under 5s’ IRR=0.84 (95% CI 0.76-0.92), ‘18 to 54s’ IRR=1.67 (95% CI 1.64-1.71), ‘55+’ 168 
IRR=1.11 (95% CI 1.09-1.13), p<0.001). Within the oldest two cohorts, as age increased exacerbations 169 
rates also increased, the opposite occurred in the youngest two cohorts (Table S1-4). Current and ex-170 
smoking was significantly associated with an increased rate in patients’ ≥18 years (Table S1-4). Patients 171 
with a ‘non-normal’ BMI (underweight, overweight or obese) had higher exacerbation rates in the ‘5 172 
to 17s’ and ’18 to 54s’ cohort (Table S1-4). Having atopy, rhinitis, reflux, anxiety, or depression 173 
increased the relative rate of exacerbations in all cohorts (Table S1-4). Exacerbation rates were also 174 
higher in asthma patients with COPD (Table S3-4). 175 
Effect of asthma severity on exacerbation rates (multivariable analysis modelling on all 176 
exacerbations) 177 
Each increase in BTS step was significantly associated with an increased rate of exacerbations 178 
compared to BTS step 1 (Figure 4). This effect was seen in all cohorts, but the largest adjusted rate 179 
ratios were found in the youngest cohort, and the smallest were found in the oldest cohort (‘Under 180 
5s’ cohort: step 2 IRR=2.3 (95% CI 2.0-2.6), step 3 IRR=4.5 (95% CI 3.7-5.5), step 4 IRR=4 (95% CI 3.5-181 
4.7), step 5 IRR=4.7 (95% CI 2.7-8.1), step 6 IRR=16.3 (95% CI 0.8-348), adjusted for age, gender, IMD, 182 
atopy, rhinitis, reflux and anxiety; ‘55+’ cohort: step 2 IRR=1.3 (95% CI 1.2-1.3), step 3 IRR=1.6 (95%CI 183 
1.5-1.6), step 4 IRR=2 (95% CI 1.9-2), step 5 IRR=2.3 (2.2-2.3), step 6 IRR=10 (95% CI 9.3-10.7), adjusted 184 
for age, gender, IMD, BMI, atopy, rhinitis, reflux, anxiety, depression and COPD (Figure 4).  185 
Effect of asthma severity on time to first exacerbation during study follow-up 186 
Time to first exacerbation analysis revealed a comparable pattern to analyses including all 187 
exacerbations. The Kaplan-Meier curves were steepest, with the shortest median times to first 188 
exacerbation, with each increasing BTS step (Figure 5 & Table S2). In general, the curves were also 189 
steepest in the following cohort order: ‘55+’, ‘Under 5s’, ’18 to 54s’ and ‘5 to 17s’ (Figure 5 & Table 190 
S2).  191 
 192 
Discussion 193 
We have undertaken the first descriptive study of the UK’s general asthma population and found many 194 
similarities and differences between the characteristics of cohorts representing: infants to 195 
preschoolers (Under 5s), young children to teenagers (5 to 17s), younger adults to middle age (18 to 196 
54s), and middle to old age (55+). One clear difference was gender; males were found to be more 197 
prevalent in the younger cohorts, <18 years but the opposite was found in the older cohorts; these 198 
results are in agreement with other prevalence, as well as incidence, asthma studies10,11. Smoking 199 
prevalence increased between the ‘5 to 17s’ and ’18 to 54s’ cohort but fell in the ‘55+’ cohort, in 200 
keeping with UK smoking data12. Adult BMI (≥ 18 years) increased with increasing cohort age, 201 
compatible with published national data13. Atopy prevalence was highest in the two youngest cohorts 202 
(< 18 years), which appears consistent with studies showing that late-onset asthma is less likely to be 203 
allergic asthma14. A history of rhinitis and reflux both showed a steady increase with age; presently 204 
there is a paucity of published data on the relationship between age and these disorders. 205 
The majority of asthma patients (>60% of the total study population) had mild asthma, BTS step 1 or 206 
2;  it is notable that this cohort only included patients with current asthma and excluded patients who 207 
had not visited their GP practice for their asthma in the last 2 or 3 years (depending on their age). 208 
However, the level of severity varied considerably between the age cohorts. The youngest and oldest 209 
cohorts, <5 years old and ≥ 55 years old, had the lowest proportion on BTS step 1. Only in the ‘Under 210 
5s’ cohort were patients more likely to have BTS step 2 than 1; this may be related to the difficulty in 211 
diagnosing asthma in children <5 years old (spirometry is often not possible and it can be difficult 212 
distinguishing asthma from ‘recurrent wheeze’) and a reluctance to diagnose until a child is more 213 
symptomatic. Asthma was more severe in the ‘55+’ cohort, in keeping with other older asthma 214 
populations15. Nearly a quarter of the ‘55+’ cohort had a record indicating concurrent COPD, in keeping 215 
with other epidemiology studies16; this could be due to misdiagnosis or the presence of features of 216 
both diseases (the ‘55+’ cohort had a high proportion with a smoking history), nearly two-thirds had 217 
their COPD diagnosed after their asthma diagnosis. Currently, there is no published study on the 218 
general UK population, but the proportion in each BTS step was similar to a study of a selected sample 219 
of UK asthma patients17.  220 
This is the first study to look comprehensively at exacerbation rates in a general asthma population. 221 
Rates were highest in the ‘55+’ cohort and lowest in the ‘5 to 17s’ cohort; in those patients that did 222 
exacerbate, the ‘Under 5s’ cohort had the highest proportion of frequent exacerbators. Although the 223 
multivariable analysis was adjusted for COPD there may have been residual confounding in the ‘55+’ 224 
cohort, including from undiagnosed COPD. For all cohorts, the majority of exacerbations were treated 225 
within primary care. The number of asthma deaths were in keeping with reported national statistics18. 226 
The rate of antibiotic treated LRTIs in association with an exacerbation was low, supporting BTS 227 
guidance not to use antibiotics for an asthma exacerbation, unless clearly clinically indicated8.  228 
Many factors significantly changed the rates of an exacerbation, including gender, age, socioeconomic 229 
deprivation, smoking history, BMI, atopy history, rhinitis history, reflux history, anxiety history, 230 
depression history and COPD history. After adjusting for these factors, increasing BTS step still 231 
significantly increased exacerbation rates. The effect was notable in all cohorts, but was more marked, 232 
for each incremental BTS step, in those aged <18 years compared to those ≥ 18 years old; suggesting 233 
that in childhood asthma the risk of an exacerbation is more influenced by the underlying disease 234 
severity than it is in adult asthma.  235 
Cluster analysis has identified a specific phenotype of older asthma patients with more severe 236 
symptoms and worse lung function19, but it is unclear how many older asthma patients are 237 
represented by this phenotype. Our study of a large general asthma cohort (where the age of disease-238 
onset is unknown) also suggests a poorer outcome for older patients (≥ 55 years), with both increased 239 
disease severity and exacerbation activity. The increase in exacerbations could be explained by the 240 
higher proportion with more severe disease, which in turn could be related to the higher proportion 241 
with asthma-severity risk factors, including a smoking history, co-existent COPD diagnosis, and 242 
reflux20–22. It has also been postulated to be related to the effects of aging (including worsening lung 243 
function, impaired response to bronchodilators and some changes in immune function), and to longer 244 
disease duration in those with early-onset asthma15,23. Furthermore, the opposite was found for the 245 
‘5 to 17s’ cohort which had the least severe asthma and lowest exacerbation activity. There is some 246 
evidence to suggest that childhood-onset asthma exhibits a better treatment response and prognosis 247 
than adult-onset asthma24, but there is a lack of knowledge regarding a general adult cohort, which 248 
would consist of patients with both early- and late-onset asthma. 249 
Our findings have shown that there is a strong association between levels of asthma treatment and 250 
exacerbation risk. Although this has not been assessed directly elsewhere, it is in keeping with another 251 
UK study, and a US study that showed high exacerbation rates in patients despite high-intensity 252 
therapy17,25. All patients should be on the lowest level of treatment required to achieve their best level 253 
of control. Therefore, the question remains whether these findings are due to suboptimal 254 
management, poor compliance, poor inhaler technique or other environmental factors, or, if some of 255 
these patients have a specific poorly-responding phenotype despite maximal pharmacological 256 
management.  257 
Limitations 258 
A possible limitation was misclassification of asthma patients, but as the Read codes used have a high 259 
positive predictive value of 86% (paper in press), this study may have excluded some asthma patients 260 
but is unlikely to have included many patients who did not have asthma. The study did not include 261 
mild exacerbations, e.g. treated by the patient themselves, as these are not routinely recorded within 262 
CPRD. Using a cut-off of 300mg for exacerbations may have excluded some exacerbations that were 263 
treated for more prolonged periods with high OCS doses, however from a sensitivity analysis changing 264 
the cut-off had little effect (Table S6). From 2007 until 2015 only 62% of A&E data were captured by 265 
CPRD; this would have reduced the number of A&E exacerbations in this study, but these were only a 266 
small proportion of total exacerbations, so any deficit is unlikely to have significantly affected the 267 
findings.  268 
There were some potential limitations in respect to the measurement of BTS step. Firstly, a defined 269 
period of one year prior to study entry was chosen, but it is possible that some patients’ BTS step 270 
changed during their follow-up. Secondly, it is possible some GP practices did not follow BTS 271 
guidelines, although most alternative national treatment guidelines (including local Clinical 272 
Commissioning Groups guidance, NICE guidelines and the British National Formulary) are created 273 
using the BTS guideline. It was notable only a small percentage of patients were not prescribed 274 
medication that fitted with the BTS stepwise approach. Lastly, the medications prescribed may not be 275 
the medication used, yet it would be expected that the prescription itself indicated the GP’s evaluation 276 
of the patient’s disease severity. The 2016 BTS guidelines are spread over 6 steps, and were not the 277 
ones used by GP practices during the study time period, which predated these guidelines. The 2016 278 
guidelines were selected due to the improved clarity in correlating ICS dosage to asthma severity. Due 279 
to the large amount of missing BMI data in the ‘Under 5s’ and ‘5 to 17s’ cohorts, the multivariate 280 
regression models for these cohorts did not include BMI. 281 
Conclusions 282 
The majority of asthma patients within the UK have mild disease and infrequent exacerbations, which 283 
are managed within primary care. There are distinct differences in characteristics across the 284 
generations of asthma patients, including gender, smoking history, atopy and asthma severity. After 285 
adjusting for multiple risk factors, the rates of exacerbations are strongly associated with disease 286 
severity, as measured using the BTS stepwise approach. 287 
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 345 
Table 1. Description of each cohort 346 
 347 
 Under 5s 5 to 17s 18 to 54s 55+ 
 N % N % N % N % 
Total 17,320  82,707  210,724  113,575  
F/U median  
(IQR, years) 1 (0.5-1.8)  3.3 (1.4-5.8)  4.0 (1.7-6.9)  5.1 (2.4-7.6)  
Gender         
Female 6,635 38.3 35,993 43.5 120,910 57.4 67,865 59.8 
Age cat*         
1 943 5.4 13,687 16.6 37,322 17.7 46,232 40.7 
2 3,738 21.6 19,370 23.4 59,239 28.1 37,226 32.8 
3 5,606 32.4 27,619 33.4 62,750 29.8 23,460 20.7 
4 7,033 40.6 22,031 26.6 51,413 24.4 6,657 5.9 
IMD**         
1 3,472 20.1 17,987 21.8 45,058 21.4 24,310 21.4 
2 3,367 19.4 17,044 20.6 45,241 21.5 27,151 23.9 
3 3,102 17.9 15,585 18.8 41,377 19.6 23,458 20.7 
4 3,772 21.8 16,765 20.3 42,673 20.3 21,356 18.8 
5 3,552 20.5 15,283 18.5 36,212 17.2 17,220 15.2 
Missing 55 0.3 43 0.1 163 0.1 80 0.1 
Smoking         
Never N/A N/A 61,506 74.4 102,684 48.7 42,815 37.7 
Current N/A N/A 3,476 4.2 54,669 25.9 14,826 13.1 
Ex N/A N/A 1,151 1.4 53,052 25.2 55,903 49.2 
Missing N/A N/A 16,574 20.0 319 0.2 31 0.0 
BMI         
Normal 7,980 46.1 23,068 27.9 69,020 32.8 29,495 26.0 
Overweight 1,018 5.9 6,393 7.7 58,786 27.9 39,274 34.6 
Obese 638 3.7 4,105 5.0 54,702 26.0 36,189 31.9 
Underweight 683 3.9 24,589 29.7 3,879 1.8 2,212 2.0 
Missing 7,001 40.4 24,552 29.7 24,337 11.6 6,405 5.6 
BTS step         
BTS1 4,889 28.2 33,109 40.0 86,360 41.0 24,980 22.0 
BTS2 6,856 39.6 26,766 32.4 54,773 26.0 24,542 21.6 
BTS3 979 5.7 3,785 4.6 18,661 8.9 12,321 10.9 
BTS4 2,227 12.9 11,782 14.3 32,821 15.6 25,714 22.6 
BTS5 97 0.6 1,148 1.4 14,663 7.0 19,425 17.1 
BTS6 <5 0.0 22 0.0 623 0.3 1,629 1.4 
Non-BTS 480 2.8 2,020 2.4 2,547 1.2 4,613 4.1 
Missing 1,790 10.3 4,075 4.9 276 0.1 351 0.3 
Atopy         
Yes 4,883 28.2 25,714 31.1 54,205 25.7 25,629 22.6 
Rhinitis         
Yes 629 3.6 6,948 8.4 23,740 11.3 14,366 12.7 
GERD         
Yes 764 4.4 1,854 2.2 17,150 8.1 19,755 17.4 
Anxiety         
Yes 290 1.7 4,260 5.2 32,844 15.6 19,610 17.3 
Depression         
Yes N/A N/A 2,238 2.7 45,489 21.6 23,397 20.6 
COPD         
Yes N/A N/A N/A N/A  5,756 2.7 25,781 22.7 
*age categories are for ‘Under 5s’: 1 (1-1.9 years), 2 (2-2.9 years), 3 (3-3.9 years), 4(4-4.9 years), ‘5 to 348 
17s’: 1 (5-7 years), 2 (8-10 years), 3 (11-13 years), 4(14-17 years), ‘18 to 54s’: 1 (18-24 years), 2 (25-349 
34 years), 3 (35-44 years), 4(45-54 years), ‘18 to 54s’: 1 (55-64 years), 2 (65-74 years), 3 (75-84 350 
years), 4 (≥85 years); **socioeconomic deprivation scale, 1 is least deprived. BTS steps are defined as 351 
1 = no regular preventer, 2 = lowest ICS dose appropriate for age (or LTRA alone if <5 years), 3 = Add 352 
LABA (add LTRA if <5 years), 4 = increase ICS dose to next level (medium in adults, low dose in 353 
children), may add in other therapy (adults: LTRA, theophylline, LAMA; children: LTRA), 5 = increase 354 
ICS dose (high in adults, medium in children), add fourth drug (adults: LTRA, theophylline, beta 355 
agonist tablet, LAMA, children: theophylline), 6 = same ICS dose and continuous or frequent use of 356 
oral steroids. LTRA = leukotriene receptor antagonist, LABA = long-acting beta-2 agonist, LAMA = 357 
long-acting muscarinic antagonist; children are patients aged under 12 years old. 358 
 359 
 360 
 361 
 362 
363 
Table 2. Summary of exacerbations and presumed bacterial LRTIs for each cohort  364 
 365 
  Under 5s 5 to 17s 18 to 54s 55 + 
  
Patients  
(%) 
Rate per 
10 person 
years 
(95% CI) 
Patients  
(%) 
Rate per 
10 person 
years 
(95% CI) 
Patients  
(%) 
Rate per 
10 person 
years 
(95% CI) 
Patients  
(%) 
Rate per 
10 person 
years 
(95% CI) 
Total cohort 17,320   82,707  210,724   113,575   
Exacerbations 7,574 
4.27 
(4.18-
4.38) 
39,970 
1.48  
(1.47-
1.50) 
245,077 
3.22 
(3.21-
3.24) 
435,029 
9.40 
(9.37-
9.42) 
Patients that  
exacerbated 
3,706  
(21.4*)   
18,449  
(22.3*)  
80,041  
(38*)   
70,954  
(62.5*)   
Annual 
exacerbation 
freq.                 
≤ 0.5 553   12,433  47,588   29,620   
0.5- 1 1,131   3,600  17,423   16,439   
1.1 - 3 1,577   2,047  12,156   17,569   
3.1 - 6 369   292  2,121   4,419   
>6 76   77   753   2,907   
Level of care                 
GP only 5,211   26,543  155,054   334,850   
A&E 232   984  2,257   561   
Hosp (<1 day) 966   6,515   46,227   50,385   
Hosp (≥1 day) 1,165   5,925  41,502   49,015   
Died <5   < 5   37   218   
Antibiotic 
treated LRTIs 
2,179 
0.61 
(0.58-
0.64) 
11,488 
0.22 
(0.21-
0.22) 
81,084 
0.71 
(0.71-
0.72) 
171,352 
1.93 
(1.92-
1.94) 
Patients with  
Ax-LRTI 
1,612  
(9.3*)   
8,252  
(10*)   
41,874  
(19.9*)   
34,656  
(30.5*)   
 366 
* % of total cohort, all other percentages are % of patients that exacerbated in that age category 367 
cohort; annual frequency is number of patients who exacerbated within each band of annual 368 
frequency. Ax-LRTI = antibiotic treated lower respiratory tract infection. 369 
  370 
Table 3. Exacerbations by patient’s BTS step and age cohort 371 
 372 
  Under 5s 5 to 17s 18 to 54s 55 + Mean 
population  
rate per 
BTS step 
  
N 
(% of BTS) 
Rate 
(95% CI) 
N 
(% of BTS) 
Rate 
(95% CI) 
N 
(% of BTS) 
Rate 
(95% CI) 
N 
(% of BTS) 
Rate 
(95% CI) 
BTS 1 
656  
(13.4) 
2.01 
(1.89-
2.14) 
4,849 
(14.6) 
0.73 
(0.70-
0.77) 
26,607 
(30.8) 
1.82 
(1.78-
1.86) 
11,805 
(47.3) 
5.01 
(4.84-
5.20) 
2.39 
(2.30-2.49) 
BTS 2 
1439  
(21.0) 
4.12  
(3.98-
4.29) 
5,958 
(22.3) 
1.41 
(1.36-
1.46) 
19,704 
(36.0) 
2.79 
(2.74-
2.85) 
14,041  
(57.2) 
6.60 
(6.41-
6.80) 
3.73 
(3.62-3.85) 
BTS 3 
343  
(35.0) 
8.57 
(8.01-
9.17) 
1,141  
(30.1) 
2.51 
(2.30-
2.76) 
8,003 
(42.9) 
3.88 
(3.75-
4.01) 
8,155 
(66.2) 
8.53 
(8.26-
8.82) 
5.87 
(5.58-6.19) 
BTS 4  
663  
(29.8) 
7.52 
(7.16-
7.91) 
4,028 
(34.2) 
2.53 
(2.41-
2.66) 
15,362 
(46.8) 
5.16 
(5.03-
5.29) 
17,638 
(68.6) 
10.83 
(10.59-
11.08) 
6.51 
(6.30-6.74) 
BTS 5 
35  
(36.1) 
10.59 
(8.59-
13.05) 
508 
(44.3) 
5.18 
(4.57-
5.88) 
8,494 
(57.9) 
8.07 
(7.84-
8.31) 
14,575 
(75.0) 
13.27 
(13.00-
13.55) 
9.28 
(8.50-10.20) 
BTS 6 
<5  
(0.0) 
31.89 
(13.27-
76.6) 
21 
(95.5) 
56.36 
(42.40-
77.21) 
547 
(87.8) 
42.1 
(39.2-
45.4) 
1,531 
(94.0) 
60.19 
(57.97-
62.52) 
47.64 
(38.21-
65.43) 
NonBTS 
131  
(27.3) 
5.58 
(4.96-
6.28) 
649 
(32.1) 
3.11 
(2.75-
3.52) 
1,211 
(47.6) 
6.90 
(6.32-
7.55) 
2,986 
(64.7) 
12.07 
(11.43-
12.75) 
6.92 
(6.37-7.53 
 373 
N is total number of patients that exacerbated, % of patients with exacerbations in that BTS category 374 
in that cohort; rates are per 10 person years. 375 
 376 
 377 
 378 
 379 
Figure 1 380 
 381 
 382 
Figure 2 383 
 384 
 385 
Figure 3 386 
 387 
 388 
Figure 5 389 
 390 
Figure 6 391 
 392 
Supplementary Table S1. Univariate analysis of demographic and clinical characteristics in ‘Under 5s’ 393 
cohort 394 
Characteristic 
 
N 
 
100 person-
years 
Rate (95% CI) 
per 100 person years 
Crude IRR (95% CI) 
 
Gender     
Male 4997 111 45 (42.8-47.4) Ref 
Female 2577 66 39.2 (36.4-42.2) 0.84 (0.76-0.92)* 
Age cat (years)     
1-1.9 884 20 43.9 (38-50.9) Ref 
2-2.9 3026 62 48.7 (45.4-52.3) 1.09 (0.9-1.32)" 
3-3.9 2694 64 42.3 (39.6-45.2) 0.93 (0.77-1.13)" 
4-4.9 970 31 31.5 (29-34.3) 0.6 (0.49-0.73)* 
IMD     
1 1227 36 33.7 (30.7-37.2) Ref 
2 1550 34 45.3 (41-50.1) 1.26 (1.09-1.46)* 
3 1306 31 42.3 (38.6-46.5) 1.23 (1.06-1.44)^ 
4 1744 38 45.7 (42-49.7) 1.3 (1.13-1.5)* 
5 1743 37 47.3 (43.3-51.9) 1.3 (1.13-1.5)* 
BMI     
Normal 3903 81 48.5 (45.9-51.4) Ref 
Overweight 483 10 47.7 (40.9-55.8) 1.06 (0.88-1.27)" 
Obese 275 6 45 (37.3-54.8) 0.97 (0.77-1.22)" 
Underweight 633 8 77.9 (66.2-92.3) 1.45 (1.19-1.78)* 
BTS step     
BTS 1 1123 56 20.2 (18.4-22.2) Ref 
BTS 2 2808 68 41.3 (38.7-44.2) 2.17 (1.93-2.44)* 
BTS 3 829 10 85.7 (75.6-97.7) 4.57 (3.76-5.55)* 
BTS 4 1552 21 75.3 (68.4-83) 3.86 (3.33-4.47)* 
BTS 5 88 1 106 (69-171.7) 4.36 (2.54-7.46)* 
BTS 6 5 0 31.89 (13.27-76.6) 13.03 (0.58-294.9)” 
Non BTS 277 5 55.8 (45.6-69.1) 3.04 (2.32-3.98)* 
Atopy     
No 4941 129 38.5 (36.6-40.4) Ref 
Yes 2633 48 54.5 (50.7-58.8) 1.33 (1.21-1.47)* 
Reflux     
No 7135 169 42.4 (40.6-44.2) Ref 
Yes 439 8 52.2 (43.4-63.3) 1.12 (0.9-1.38)" 
Anxiety     
No 7416 174 42.6 (40.9-44.5) Ref 
Yes 158 3 56.9 (39.8-84.1) 1.22 (0.87-1.72)" 
Season     
Winter 2018 9 219.3 (209.9-229) Ref 
Spring 1900 8 243.1 (232.4-254.3) 1.11 (1.1-1.12)* 
Summer 1348 6 218.3 (207-230.3) 1.09 (1.08-1.1)* 
Autumn 2308 11 206.6 (198.4-215.2) 1 (0.99-1.01)" 
N exacerbations; rate: per 100 person years; p-values: * p<0.001, ^ p<0.05, “p>0.05; IMD, 1 is least 395 
deprived 396 
  397 
 398 
Supplementary Table S2. Univariate analysis of demographic and clinical characteristics in ‘5 – 17s’ 399 
cohort 400 
Characteristic 
 
N 
 
100 person-
years 
Rate (95% CI) 
per 100 person years 
Crude IRR (95% CI) 
 
Gender     
Male 22772 1555 14.7 (14.3-15.1) Ref 
Female 17198 1141 15.1 (14.6-15.7) 1 (0.95-1.04)" 
Age cat (years)     
5-7 14755 772 19.2 (18.4-20) Ref 
8-10 12393 830 15 (14.3-15.7) 0.75 (0.71-0.79)* 
11-13 8807 743 11.9 (11.4-12.5) 0.58 (0.55-0.62)* 
14-17 4015 352 11.5 (10.8-12.1) 0.51 (0.48-0.54)* 
IMD     
1 7827 624 12.6 (11.9-13.3) Ref 
2 7957 557 14.3 (13.6-15.1) 1.13 (1.06-1.21)* 
3 7508 501 15 (14.2-15.9) 1.2 (1.12-1.28)* 
4 8405 535 15.8 (15-16.6) 1.23 (1.15-1.32)* 
5 8255 478 17.3 (16.4-18.3) 1.39 (1.3-1.49)* 
Smoking     
Never 33471 2154 15.6 (15.2-16) Ref 
Current 856 64 13.4 (12.2-14.9) 0.96 (0.85-1.08)" 
Ex 368 22 16.9 (13.8-20.9) 1.18 (0.97-1.43)" 
BMI     
Normal 11209 709 15.9 (15.2-16.6) Ref 
Overweight 3232 186 17.4 (16.1-19) 1.15 (1.06-1.25)* 
Obese 2251 126 18 (16.4-19.7) 1.13 (1.02-1.24)^ 
Underweight 16256 913 17.9 (17.1-18.6) 1.2 (1.14-1.27)* 
BTS step     
BTS 1 8196 11000 7.3 (6.9-7.7) Ref 
BTS 2 11301 8000 14.1 (13.6-14.6) 2.05 (1.95-2.16)* 
BTS 3 2740 1100 25.1 (23-27.6) 3.37 (3.07-3.71)* 
BTS 4 10732 4200 25.3 (24.1-26.6) 3.76 (3.54-4)* 
BTS 5 1858 359 51.8 (45.7-58.8) 7.21 (6.18-8.41)* 
BTS 6 387 7 563.6 (424-772.1) 
60.71 (23.13-
159.36)* 
Non BTS 1793 577 31.1 (27.5-35.2) 4.45 (3.93-5.04)* 
Atopy     
No 24132 1824 13.3 (12.9-13.7) Ref 
Yes 15838 873 18.2 (17.5-18.9) 1.36 (1.3-1.42)* 
Reflux     
No 38493 2637 14.6 (14.3-15) Ref 
Yes 1477 59 25.1 (21.1-30) 1.59 (1.39-1.83)* 
Anxiety     
No 37510 2554 14.7 (14.4-15.1) Ref 
Yes 2460 143 17.3 (15.5-19.3) 1.09 (1-1.2)" 
Depression     
No 38790 2636 14.8 (14.4-15.1) Ref 
Yes 1180 60 19.6 (17.2-22.5) 1.18 (1.03-1.34)^ 
COPD     
No 39781 2688 0 (0-0) Ref 
Yes 189 8 0 (0-0) 1.4 (0.97-2.02)" 
Season     
Winter 10430 145 71.9 (70.6-73.3) Ref 
Spring 9877 126 78.2 (76.7-79.7) 1.12 (1.08-1.16)* 
Summer 8589 113 76.2 (74.6-77.9) 1.08 (1.04-1.12)* 
Autumn 11074 146 76 (74.6-77.4) 1.02 (0.99-1.05)" 
N exacerbations; rate: per 100 person years; p-values: * p<0.001, ^ p<0.05, “p>0.05; IMD, 1 is least 401 
deprived 402 
  403 
Supplementary Table S3. Univariate analysis of demographic and clinical characteristics in ‘18 – 54s’ 404 
cohort 405 
Characteristic 
 
N 
 
100 person-
years 
Rate (95% CI) 
per 100 person years 
Crude IRR (95% CI) 
 
Gender     
Male 76254 3351 22.8 (22.3-23.3) Ref 
Female 168823 4240 39.9 (39.3-40.4) 1.67 (1.64-1.71)* 
Age cat (years)     
18-24 28503 1334 21.4 (20.8-22) Ref 
25-34 57976 2115 27.5 (26.9-28.1) 1.22 (1.19-1.26)* 
35-44 91169 2637 34.6 (33.9-35.3) 1.51 (1.47-1.55)* 
45-54 67429 1505 44.9 (43.8-45.9) 1.97 (1.91-2.03)* 
IMD     
1 39105 1729 22.7 (22.1-23.3) Ref 
2 46958 1648 28.6 (27.8-29.3) 1.23 (1.19-1.27)* 
3 47393 1473 32.2 (31.4-33.1) 1.39 (1.35-1.44)* 
4 55104 1497 36.9 (35.9-37.8) 1.58 (1.53-1.62)* 
5 56391 1239 45.6 (44.5-46.7) 1.93 (1.87-1.99)* 
Smoking     
Never 100753 3822 26.4 (25.9-26.9) Ref 
Current 80844 1933 41.9 (41-42.7) 1.57 (1.54-1.61)* 
Ex 63469 1829 34.8 (34-35.6) 1.32 (1.29-1.35)* 
BMI     
Normal 69182 2501 27.7 (27.1-28.3) Ref 
Overweight 66585 2161 30.9 (30.2-31.5) 1.12 (1.1-1.15)* 
Obese 89918 1958 46 (45.1-46.9) 1.63 (1.59-1.67)* 
Underweight 5084 136 37.4 (34-41.3) 1.33 (1.24-1.42)* 
BTS step     
BTS 1 62730 35000 18.2 (17.8-18.6) Ref 
BTS 2 50228 18000 27.9 (27.4-28.5) 1.51 (1.47-1.55)* 
BTS 3 24359 6400 38.8 (37.5-40.1) 2.05 (1.99-2.12)* 
BTS 4 54192 11000 51.6 (50.3-52.9) 2.68 (2.61-2.75)* 
BTS 5 39217 4900 80.7 (78.4-83.1) 4.1 (3.96-4.25)* 
BTS 6 8450 200 421.3 (391.7-453.6) 
20.88 (18.17-
23.98)* 
Non BTS 5369 798 69 (63.2-75.5) 3.54 (3.27-3.82)* 
Atopy     
No 167639 5544 30.3 (29.9-30.7) Ref 
Yes 77438 2047 37.9 (37.1-38.7) 1.21 (1.18-1.23)* 
Reflux     
No 208090 6939 30 (29.7-30.4) Ref 
Yes 36987 652 56.8 (54.9-58.8) 1.78 (1.72-1.84)* 
Anxiety     
No 187540 6339 29.6 (29.2-30) Ref 
Yes 57537 1252 46 (44.9-47.2) 1.5 (1.46-1.54)* 
Depression     
No 163724 5928 27.7 (27.3-28.1) Ref 
Yes 81353 1663 49 (48-50) 1.71 (1.68-1.75)* 
COPD     
No 227779 7443 30.7 (30.3-31) Ref 
Yes 17298 148 116.9 (111.5-122.6) 3.4 (3.21-3.6)* 
Season     
Winter 65630 817 80.3 (79.7-80.9) Ref 
Spring 59958 691 86.8 (86.1-87.5) 1.1 (1.09-1.12)* 
Summer 56396 646 87.3 (86.5-88) 1.07 (1.06-1.09)* 
Autumn 63093 757 83.4 (82.7-84) 1 (0.98-1.01)" 
N exacerbations; rate: per 100 person years; p-values: * p<0.001, ^ p<0.05, “p>0.05; IMD, 1 is least 406 
deprived 407 
  408 
Supplementary Table S4. Univariate analysis of demographic and clinical characteristics in ‘55+’ 409 
cohort 410 
Characteristic 
 
N 
 
100 person-
years 
Rate (95% CI) 
per 100 person years 
Crude IRR (95% CI) 
 
Gender     
Male 161258 1845 87.5 (85.8-89.2) Ref 
Female 273771 2785 98.3 (96.8-99.9) 1.11 (1.09-1.13)* 
Age cat (years)     
55-64 151439 2012 75.3 (73.8-76.8) Ref 
65-74 161024 1576 102.2 (100.2-104.3) 1.36 (1.33-1.39)* 
75-84 103650 869 119.3 (116.3-122.4) 1.63 (1.59-1.68)* 
85+ 18916 173 109.3 (103.6-115.3) 1.64 (1.57-1.71)* 
IMD     
1 82641 1042 79.4 (77.1-81.7) Ref 
2 101774 1119 91 (88.8-93.3) 1.13 (1.1-1.16)* 
3 89705 942 95.3 (92.7-97.9) 1.19 (1.16-1.23)* 
4 84986 847 100.4 (97.7-103.1) 1.23 (1.2-1.27)* 
5 75663 676 111.9 (108.8-115.1) 1.36 (1.32-1.41)* 
Smoking     
Never 141855 1817 78.1 (76.5-79.9) Ref 
Current 64605 580 111.5 (108.3-114.8) 1.37 (1.33-1.41)* 
Ex 228533 2233 102.4 (100.7-104.1) 1.29 (1.26-1.31)* 
BMI     
Normal 114822 1189 96.6 (94.3-99.1) Ref 
Overweight 151104 1666 90.7 (88.9-92.6) 0.91 (0.89-0.94)* 
Obese 144957 1521 95.3 (93.5-97.3) 0.96 (0.93-0.98)* 
Underweight 9407 67 140.2 (129.1-152.5) 1.49 (1.39-1.6)* 
BTS step     
BTS 1 55299 1100 50.1 (48.4-52) Ref 
BTS 2 64519 978 66 (64.1-68) 1.28 (1.24-1.31)* 
BTS 3 43565 511 85.3 (82.5-88.2) 1.63 (1.58-1.69)* 
BTS 4 110858 1000 108.3 (105.9-110.8) 2.06 (2-2.11)* 
BTS 5 103228 778 132.7 (130-135.5) 2.47 (2.4-2.55)* 
BTS 6 35276 59 601.9 (579.7-625.2) 
11.52 (10.71-
12.38)* 
Non BTS 20206 167 120.7 (114.3-127.5) 2.25 (2.14-2.36)* 
Atopy     
No 321078 3507 91.6 (90.3-92.9) Ref 
Yes 113951 1123 101.5 (99.1-104) 1.08 (1.05-1.1)* 
Reflux     
No 339108 3775 89.9 (88.7-91.1) Ref 
Yes 95921 855 112.3 (109.4-115.2) 1.21 (1.18-1.24)* 
Anxiety     
No 342657 3792 90.4 (89.2-91.7) Ref 
Yes 92372 839 110.2 (107.3-113.2) 1.2 (1.17-1.23)* 
Depression     
No 329034 3673 89.6 (88.4-90.9) Ref 
Yes 105995 957 110.8 (108.1-113.6) 1.21 (1.19-1.24)* 
COPD     
No 304241 3754 81.1 (79.9-82.3) Ref 
Yes 130788 876 149.3 (146.2-152.5) 1.78 (1.74-1.82)* 
Season     
Winter 114083 866 131.7 (130.9-132.4) Ref 
Spring 112214 765 146.6 (145.7-147.5) 1.11 (1.10-1.12)* 
Summer 102679 671 152.9 (152-153.9) 1.09 (1.08-1.10)* 
Autumn 106053 749 141.6 (140.8-142.5) 1.00 (0.99-1.01)” 
N exacerbations; rate: per 100 person years; p-values: * p<0.001, ^ p<0.05, “p>0.05; IMD, 1 is least 411 
deprived 412 
  413 
Table S5. Median time to first exacerbation by age group and BTS step 414 
  Median time without an exacerbation (years) 
  Under 5s 5-17s 18-54s 55+ 
BTS 1 > 4  >8.5 >8.5 5.3 
 BTS 2 > 4  >8.5 5.9 3.4 
BTS 3 2.4 7.4 4.4 2.5 
BTS 4 2.8 8.4 3.6 2 
BTS 5 1.3 3.8 2.1 1.4 
BT S6 0.34 0.1 0.2 0.1 
Log-rank test p<0.001 415 
 416 
 417 
